Cue Biopharma, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Cue Biopharma, Inc. (CUE) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2022-11-14
- 2022-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2022-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2022-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.00M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 |
| 2022-03-31 | $2.00M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |